ABVC BioPharma entered into a global licensing definitive agreement with AiBtl BioPharma for the Company’s CNS drugs with the indications of MDD and ADHD. The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation. ABVC and AiBtl are determined to work to strengthen their new drug development and business collaboration. This definitive agreement brings licensing revenues for ABVC and its subsidiary BioLite, Inc. as AiBtl stock of 46 million shares worth $460M and milestone cash payments of $7M with the royalties of 5% of net sales, up to $200 million, after the product’s launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABVC:
- ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
- ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
- ABVC BioPharma reports Q3 EPS (82c) vs ($1.14) last year
- ABVC BioPharma enters into term sheet to license global rights of CNS drugs
- ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million